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Abstract
More than a decade after West Nile virus (WNV) entered North America, and despite a significant increase in reported cases
during the 2012 and 2013 seasons, no treatment or vaccine for humans is available. Although antiviral T cells contribute to
the control of WNV, little is known about their regulation during acute infection. We analyzed the expression of Tim-3 and
PD-1, two recently identified T cell negative immune checkpoint receptors, over the course of WNV infection. Symptomatic
WNV+ donors exhibited higher frequencies of Tim-3+ cells than asymptomatic subjects within naı¨ve/early differentiated
CD28+/–CD57–CD4+ and differentiated CD28–CD57–CD8+ T cells. Our study links Tim-3-expression on T cells during acute
WNV infection with the development of symptomatic disease, suggesting Tim-3 and its ligands could be targeted
therapeutically to alter anti-WNV immunity and improve disease outcome.
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Introduction
Over the past 13 years West Nile virus (WNV) has been
responsible in the United States (US) alone for more than 38,000
documented infections, of which 16,453 developed neuroinvasive
disease, and 1,579 died [1]. Based on serological analysis, it is
projected that over 3 million people were infected with WNV in
the US from 1999 to 2010 [2]. With no specific treatment or
vaccine licensed against WNV for use in humans, an improved
understanding of host-virus interface and novel approaches to
therapy are needed.
Increased age [3] and host genetic background [4,5,6] have
been associated with symptomatic disease or failure to control
WNV infection. Studies in rodents and humans have established
the importance of innate and adaptive immunity in the control
and clearance of WNV infection and prevention of its complica-
tions [7]. Immunocompromised humans and animals develop
more severe symptoms and disease after WNV infection [8]. The
humoral immune response is important in the control of WNV
viremia and prevention of spread to the central nervous system,
and antiviral T cells function to clear WNV from infected tissues
and limit the extent of WNV disease in the central nervous system
(CNS) [7].
Although WNV-specific CD8+ T cell responses are required to
clear WNV from the CNS, these responses can contribute to
immunopathology, which is characterized by excessive neuronal
injury and inflammation [9,10]. Although research has begun to
clarify the relationship between immune protection and disease,
the precise correlates of protective T cell immunity in humans
remain uncharacterized. Determining the nature of protective
rather than pathogenic T cell responses and identifying strategies
to modulate such activities could reduce the risks of neurological
complications or death in recently infected persons, as well as
inform vaccine strategies that optimize cell-mediated immune
responses.
Several counter-regulatory mechanisms have been suggested to
control the functional fate of T cells. While negative regulatory
mechanisms limit host tissue damage by dampening inflammation,
this could have adverse effects by suppressing requisite antiviral
effector T cell responses [11]. In the course of chronic antigen
persistence during viral infection, T cells advance through
sequential stages of ‘exhaustion’ that are characterized by
expression of multiple inhibitory receptors, including the pro-
grammed death-receptor 1 (PD-1) [12], which is associated with T
cells retaining proliferative but losing cytokine production
capacities, and the T cell immunoglobulin and mucin domain 3
receptor (Tim-3), which is linked to poor proliferative and
polyfunctional cytokine production capacities in T cells [12].
Higher expression of Tim-3 on PD-1 expressing T cells correlates
with clinical progression in multiple chronic viral infections [13].
However, the role of inhibitory T cell receptor checkpoints in
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acute viral infections such as WNV remains less well character-
ized.
The present study investigated the dynamics of Tim-3 and PD-1
inhibitory receptor expression through the evolution of acute
WNV infection. Our results reveal an association between
increased frequencies of Tim-3+ T cells and the development of
symptomatic WNV disease in humans, suggesting that Tim-3 and
its ligands could be targeted therapeutically to limit the
development of symptomatic WNV disease.
Materials and Methods
Human subjects
Thirty-two WNV-infected subjects were enrolled in 2007 by the
Blood Systems Research Institute (BSRI, San Francisco, CA) from
donors in United Blood Services blood centers throughout the US.
Blood donors whose donation tested positive for WNV RNA
(WNV+) with the WNV Procleix transcription mediated amplifi-
cation assay (Novartis Diagnostics) were enrolled in follow-up
Table 1. WNV+ subject characteristics.
Subject Symptom number Genderb Age IgMc IgGc Donor Statusd
Before
donation
Index
donation
After
donation
Peak
symptom
numbera
267 0 0 0 0 F 52 - - AS
247 1 0 N/A 1 F 29 - - AS
257 0 0 1 1 M 58 - - AS
437 1 0 0 1 F 57 - - AS
227 1 0 1 1 F 69 - - AS
17 2 2 0 2 M 52 - - AS
207 1 1 2 2 F 57 - - AS
357 0 0 2 2 F 46 - - AS
387 2 0 0 2 F 18 - - AS
137 2 0 N/A 2 M 63 - - AS
407 0 1 2 2 F 65 - - AS
127 3 0 0 3 M 26 - - AS
327 3 0 0 3 M 58 - - AS
77 0 0 0 0 M 77 + - AS
497 0 0 0 0 F 69 + - AS
517 0 0 N/A 0 F 65 + - AS
487 2 0 0 2 F 65 + - AS
177 0 0 0 0 M 60 + + AS
367 0 0 0 0 M 36 + + AS
187 1 0 1 1 M 37 + + AS
297 2 0 0 2 F 61 + + AS
307 0 0 0 0 M 38 + E AS
627 2 1 0 2 F 60 + E AS
57 0 1 0 1 M 69 E + AS
87 1 0 4 4 F 59 - - S
477 0 0 4 4 M 65 - - S
47 0 0 5 5 F 25 - - S
277 6 5 0 6 F 32 - - S
37 0 0 8 8 M 49 - - S
117 8 5 2 8 F 46 - - S
317 0 0 9 9 F 38 - - S
397 9 2 N/A 9 M 26 - - S
N/A, not available.
aHighest number of symptoms reported on either questionnaire.
bFemale (F) and male (M).
cAntibody interpretation at index: positive (+), negative (2), or equivocal (E).
dAS is for asymptomatic when peak symptom number #3 and S is for symptomatic when peak symptom number $4.
doi:10.1371/journal.pone.0092134.t001
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studies after obtaining written informed consent. Questionnaires
were administered to determine symptoms during the three week
period around initial blood donation (index). Samples were
collected at regional blood centers during follow-up visits and
shipped to BSRI. Based on symptom data, WNV+ blood donors
were classified as asymptomatic (n = 24) or symptomatic (n = 8) as
previously described [14]. The control subjects in this study
included 16 apheresis blood donors who tested negative for WNV
RNA (WNV2) (no demographic data available) and 10 healthy
controls who had provided written consent and were negative for
WNV IgM. The research involving human participants reported
in this study was approved by the UCSF Committee on Human
Research (IRB # 10-01255 and # 11-06262).
Peripheral blood mononuclear cell isolation
The peripheral blood mononuclear cells (PBMCs) and plasma
used in this study were derived from blood drawn from 32 WNV+
blood donors at regional blood centers. Samples were processed
within 24 hours, with PBMCs and plasma cryopreserved for future
use. The samples used in this study were collected a mean of 14
days, 1 month, 3 months, and 12 months post-index donation.
The PBMCs from the 16 WNV- uninfected donors were derived
from discarded leukoreduction chambers collected on apheresis
machines after platelet donations and were cryopreserved in liquid
nitrogen [15].
Human flow cytometry analysis
Cryopreserved human PBMCs were thawed and stained with
the LIVE/DEADH aqua amine-reactive dye (Invitrogen). The
cells were washed and surface-stained with a cocktail of antibodies
consisting of Energy Coupled Dye (ECD)-conjugated anti-CD3
(clone UCHT1, Beckman Coulter), Alexa FluorH 700 (A700)-
conjugated anti-CD4 (clone RPA-T4, BD Pharmingen), APC-
Cyano dye 7 (APC-Cy7)-conjugated anti-CD8 (clone SK1, BD
Pharmingen), Phycoerythrin-Cyano dye 7 (PE-Cy7)-conjugated
anti-CD28 (clone CD28.2, eBioscience), Fluorescein isothiocya-
nate (FITC)-conjugated anti-CD57 (clone HCD57, BioLegend),
Phycoerythrin (PE)-conjugated anti-Tim-3 (clone 344823, R&D
Systems, Inc.), and Allophycocyanin (APC)-conjugated anti-PD-1
(clone EH12.2H7, BioLegend) antibodies. Cells were then washed
and fixed with BD Stabilizing Fixative buffer (BD Bioscience). In
separate experiments cells were stained with the LIVE/DEADH
aqua amine-reactive dye and surface-stained with PE-conjugated
HLA-A02-restricted SVG9 (E peptide) tetramers [16] (prepared
by the NIH Tetramer Facility, Atlanta, GA) for 45 minutes at
37uC before being washed and surface-stained with a cocktail of
antibodies consisting of ECD-conjugated anti-CD3 (clone
UCHT1, Beckman Coulter), APC-Cy7-conjugated anti-CD8
(clone SK1, BD Pharmingen), and A700-conjugated anti-Tim-3
(Clone 344823, R&D Systems, Inc.) monoclonal antibodies (mAbs)
before final wash and fixation in BD Stabilizing Fixative buffer
(BD Bioscience). In separate experiments cells were incubated for
2 hours before the addition of Brefeldin A (5 mg/mL) for overnight
incubation in unstimulated and stimulated conditions with anti-
CD3 plus anti-CD28 mAbs (BD Pharmingen), with a pool of 8
WNV peptides corresponding to immunodominant CD8+ T cell
epitopes in membrane, envelope, and nonstructural 3 and 4B
proteins identified in WNV+ subjects [17] (using 10 mg/mL of
individual peptides) along with the HLA-A02-restricted SVG9
peptide (at a 1/200 dilution from a 1.2 mg/mL stock solution in a
final volume of 100 mL of RPMI-1640 with 10% FBS). Cells were
stained with the LIVE/DEADH aqua amine-reactive dye, washed
and surface stained with FITC-conjugated anti-CD4 (clone
OKT4, BioLegend), APC-Cy7-conjugated anti-CD8 (clone SK1,
BD Bioscience), and BV421-conjugated anti-Tim-3 (Clone F38-
2E2, BioLegend) mAbs. After washing, cells were fixed and
permeabilized with Caltag mediums A and B (Invitrogen) before
addition of ECD-conjugated anti-CD3 (clone UCHT1, Beckman
Coulter) and APC-conjugated IFN-c (clone B27, BioLegend)
mAbs. Then cells were washed and fixed in 1% paraformalde-
hyde. The cells used for FMO conditions were stained and
acquired in parallel. The acquisition was performed using an
LSRII instrument (BD Biosciences). At least 100,000 events were
collected and analyzed with the FlowJo software (TreeStar).
Statistical analysis
GraphPad Prism and R statistical software was used for data
analysis. A two-tailed t test was used where appropriate. For data
with non-Gaussian distributions (i.e., cell marker frequency
measurements), the non-parametric Mann-Whitney rank sum test
for two independent populations was performed. The false
discovery rates (FDR) were derived from the Benjamini and
Hochberg procedure. While accounting for data dependency, the
generalized estimating equations (GEE) method was used to
compare the panels of multiple longitudinal measurements.
Statistical significance was considered for p-values ,0.05 and
FDRs#0.1.
Results
Symptomatic WNV+ subjects have higher frequencies of
Tim-3-expressing CD4+ and CD8+ T cells than
asymptomatic WNV+ subjects
We characterized the cell surface expression of Tim-3 and PD-1
on T cells over the course of acute WNV infection in a cohort of
WNV-positive (WNV+) human blood donors followed from the
earliest stage of viremia (Table 1) throughout convalescence [18].
The proportion of Tim-3 and PD-1 expressing CD4+ and CD8+ T
cells was measured by flow cytometry (Figure 1) from PBMCs
collected at days 14, 30, 90, and 365 after blood donation (post-
index) from 32 WNV+ blood donors, and was compared to cells
collected at a single time-point from 26 WNV-negative normal
controls (WNV2).
WNV+ subjects could be segregated based on their clinical
presentation during the acute viremic phase into asymptomatic
and symptomatic WNV+ subjects (Table 1) [14]. We observed
higher frequencies of total Tim-3+ CD4+ T cells in symptomatic
WNV+ subjects compared to asymptomatic WNV+ subjects as
early as day 14 post-index (p = 0.0009 FDR = 0.003) (Figure 2A)
with symptomatic WNV+ subjects maintaining significantly higher
frequencies of Tim-3+ CD4+ T cells throughout the course of
WNV infection (overall GEE, p = 0.004) (Figure 2A). In contrast,
Figure 1. Gating strategy for measuring Tim-3 and PD-1 inhibitory receptors on T cells. The plots show (A) the gating strategy for live
CD3+ lymphocytes, (B) for CD4+ (left) and CD8+ (right) T cells. Gates were set on FMO no Tim-3 (C) and FMO no PD-1 (D). The gating of cells expressing
Tim-3 and PD-1 is shown for representative (E) WNV2 and (F) WNV+ subjects day 14 post-index donation.
doi:10.1371/journal.pone.0092134.g001
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asymptomatic and symptomatic WNV+ subjects expressed similar
frequencies of PD-1+ T cells (Figure 2B). Symptomatic WNV+
subjects exhibited significantly higher frequencies of Tim-3+PD-12
CD4+ T cells (p,0.05 FDR,0.05) (Figure 2C) and Tim-3+ PD-
1+ CD4+ T cells (p = 0.015 FDR = 0.06) (Figure 2D) as well as
Tim-3+ PD-1+ CD8+ T cells (p = 0.023 FDR = 0.09) than
asymptomatic WNV+ subjects at day 14 post index.
Symptomatic WNV+ subjects exhibit higher frequencies
of early differentiated (CD28+/2CD57) Tim-3+ T cell
populations
We measured the frequencies of differentiated T cells based on
CD28 and CD57 expression over the course of WNV infection by
flow cytometry (Figure 3) to assess the frequencies of Tim-3+ T
cells within naı¨ve/early differentiating (CD28+/2CD572), differ-
entiated (CD282CD572), and senescent (CD282CD57+) T cell
subsets in asymptomatic and symptomatic WNV+ subjects
(Figure 4). Symptomatic WNV+ subjects had higher frequencies
of Tim-3+ naı¨ve/early differentiating and CD4+ T cells compared
to asymptomatic WNV+ subjects from the earliest time-point at
day 14 post-index (p AS vs. S,0.0001, FDR = 0.002) and
throughout WNV infection (overall GEE, p,0.01 for both subsets)
(Figure 4A). Symptomatic WNV+ subjects also exhibited higher
frequencies of Tim-3+ differentiated CD8+ T cells than the
asymptomatic WNV+ subjects at 14 days post-index (p AS vs.
S = 0.02, FDR = 0.107) and throughout WNV infection (overall
GEE, p = 0.043) (Figure 4B). Notably, asymptomatic and
symptomatic WNV+ subjects expressed similar frequencies of
senescent T cells throughout and after resolution of WNV
infection.
While Tim-3+ T cells are responsible for most of the IFN-c
secretion, both Tim-3+ and Tim-32 T cells are competent
for IFN-c secretion
To characterize further the functional state of the Tim-3+ T
cells, we examined cytokine responses from PBMCs obtained from
6 HLA-A02 WNV+ donors incubated ex vivo with or without anti-
CD3 and anti-CD28 monoclonal antibodies, a WNV peptide pool
corresponding to immunodominant T cell epitopes in membrane,
envelope, and nonstructural 3 and 4B proteins [17], or an SVG9
peptide (HLA02 restricted SVGGVFTSV peptide in E) [16] by
flow cytometry (Figure 5). In all conditions, the majority of IFN-
c-secreting T cells were Tim-32 (Figure 6A and B). However,
the ratios of IFN-c+ cells within the Tim-32 and Tim-3+ CD4+
(Figure 6C) and CD8+ T cells (Figure 6D) were similar if not
higher in the Tim-3+ T cells.
Discussion
In this longitudinal study, we assessed the dynamics of
expression of immune inhibitory receptors during the evolution
of acute WNV infection. Our experiments revealed that symp-
tomatic WNV+ donors exhibited higher frequencies of Tim-3+
and Tim-3+PD-1+ T cells compared to asymptomatic WNV+
donors throughout the course of infection, and Tim-3+ populations
phenotypically were CD28+ CD572 naı¨ve/differentiating and
CD282 CD572 differentiated CD4+ and CD8+ T cells. This is the
first report documenting the induction of Tim-3+PD-1+ T cells
after WNV infection and the association between the frequency of
Tim-3+ T cells and WNV disease outcome.
The increased expression of negative inhibitory receptors on T
cells has been observed in chronic viral infections and cancers.
Under these conditions, a phenomenon of T cell exhaustion
develops that has been associated with higher antigen load or
longer antigen exposure. Antibody blockade of exhaustion markers
leads to an improvement in antiviral and anti-tumor T cell
immunity, reduced viremia or tumor burden, and reduced severity
of disease outcome [19,20,21,22,23]. Tim-3+PD-1+ T cell induc-
tion in the acute phase of HCV infection correlated with defective
T cell responses and may contribute to the lack of immune control
and development of persistence [19]. Unexpectedly, a recent study
examining acute Mycobacterium tuberculosis infection in humans
found that Tim-3+ T cells were more active and effective in
suppressing mycobacterial infection in macrophages, suggesting a
possible differential role for Tim-3 in an acute bacterial infection
[24].
WNV infection is an acute viral infection, which in the majority
of individuals resolves within a few weeks of exposure, although
the virus may persist in some humans [25,26] and mice [27]. The
expression of T cell exhaustion markers, such as Tim-3 and PD-1,
has not been investigated extensively in acute viral infections. One
recent study, reported a protective role of Tim-3 in acute influenza
infection in mice [28]. Our findings, in contrast, suggest that
individuals with higher frequencies of Tim-3+ T cells after WNV
infection experience symptomatic disease. In mice, severe disease
following influenza infection may be due more to the immune
response and less to the virus directly [29], whereas WNV directly
promotes injury and death of some neuronal subtypes once it
reaches the CNS [7]. Thus, the difference in pathogenesis and
mechanism of injury may explain the discrepant results between
acute influenza and WNV infection.
The reasons for increased frequencies of Tim-3+ T cells in
symptomatic WNV+ subjects are not clear. Whether symptomatic
WNV+ subjects developed higher frequencies of Tim-3+ T cells
after WNV infection or had higher levels of these cells prior to
infection remains to be established. With no pre-WNV infection
samples available, our human studies are limited to an association
between elevated Tim-3+ T cell frequencies and symptomatic
disease. The functional characterization of T cells ex vivo after
restimulation revealed that while Tim-3+ T cells secrete IFN-c,
most of the IFN-c is secreted by Tim-32 T cells. In the context of
WNV infection, Tim-3+ T cells might be less functional, as
reported in other infectious models [12]. Taken together, these
results demonstrated that Tim-3+ T cells triggered after WNV
Figure 2. Frequencies of Tim-3 and PD-1 expressing T cells compared over the course of WNV infection in groups with different
disease outcome. The graphs below demonstrate the change of frequencies of (A) Tim-3+, (B) PD-1+, (C) Tim-3+PD-12, and (D) Tim-3+PD-1+ CD4+
(left panel) and CD8+ (right panel) T cell subsets in asymptomatic (AS, circles/solid lines, n = 24) and symptomatic (S, squares/dash lines, n = 8) WNV-
infected subjects 14, 30, 90, and 365 days post-index donation. The frequencies of the same cells in uninfected controls are displayed (WNV2,
triangles, n = 26). The symbols indicate the means and the error bars represent the SEM. The p-values of the pairwise comparisons between
asymptomatic and symptomatic groups are indicated by *p,0.05, ** p,0.01, and *** p,0.001 above time-points when groups were compared at a
given time-point by Mann-Whitney test. The p-values of the comparison between asymptomatic and symptomatic groups are indicated by **
adjacent to the cell subset title for p ,0.01 over the time of post-index by generalized estimated equation (GEE).
doi:10.1371/journal.pone.0092134.g002
Tim-3+ T Cell Dynamics and WNV Disease Outcome
PLOS ONE | www.plosone.org 6 March 2014 | Volume 9 | Issue 3 | e92134
Tim-3+ T Cell Dynamics and WNV Disease Outcome
PLOS ONE | www.plosone.org 7 March 2014 | Volume 9 | Issue 3 | e92134
infection a priori are not less functional in terms of IFN-c secretion
than the Tim-32 T cells even though most of the IFN-c response
comes from Tim-32 cells.
We observed an association between symptomatic disease
outcome and Tim-3+ T cells with a CD28+/2CD572 naı¨ve/early
differentiated cellular profile. Recent studies reported that Tim-3
expression can be induced in naı¨ve [30,31], effector, and memory
T cells in an antigen-independent manner by cytokines, such as
IL-2, IL-7, IL-15 and IL-21, and also can be expressed on the
surface of naı¨ve, effector, and memory T cells [30]. In the context
of an acute viral infection this may impact the generation of an
effective antiviral T cell response. We envision that during acute
WNV infection, premature immune exhaustion among early
differentiating T cells could blunt the T cell responses that are
required to control and clear the virus, especially in the later
phases of pathogenesis. Whether symptomatic WNV+ subjects
develop higher, more persistent viremia and/or inflammation
remains to be investigated. Placing our data into the context of
prior studies showing that PBMCs from symptomatic WNV+
subjects’ PBMCs preferentially secrete IFN-c in response to WNV
peptide restimulation [17], and that lower levels of Tregs circulate
in symptomatic WNV+ subjects [14], we propose that, in
symptomatic WNV+ subjects, higher antigen load and inflamma-
tory responses could lead to increased cellular activation, with
Tim-3 marking a population of hyperactivated cells. Alternatively,
sustained or high levels of viral infection and inflammation could
induce expression of inhibitory receptors, with Tim-3+ on T cells
acting to limit collateral immune-mediated damage to host tissues.
Nonetheless, this counter-regulatory activity could be detrimental
if blunted T cell responses allowed WNV to persist longer in the
CNS, where the virus is cytopathic for neurons [7]. In this
scenario, targeting of Tim-3+ T cells (antibody blockade or
depletion) might boost the T cell immune response to control viral
replication and reduce disease severity, as reported for chronic
viral infections (HIV, HCV, and HBV) [13,19,32]. Clearly, further
investigation is required to determine whether higher frequencies
of Tim-3+ T cells are the cause or the consequence of symptomatic
WNV disease.
Figure 3. Gating strategy for measuring CD28 differentiation and CD57 senescence makers on T cells. The plots show (A) the gating
strategy for live CD3+ lymphocytes, (B) for CD4+ (left) and CD8+ (right) T cells. Gates were set on FMO no CD28 (C) and FMO no CD57 (D). Plots are
shown for representative (E) West Nile virus (WNV) uninfected controls (WNV2) and (F) WNV infected subjects (WNV+) day 14 post-index donation.
doi:10.1371/journal.pone.0092134.g003
Figure 4. Differentiation status and functional capacity of Tim-3+ T cells in acute West Nile virus infection. The graphs show, through
the course of WNV infection, the frequencies of Tim-3+ CD28+CD572, CD282CD572 and CD282CD57+ (A) CD4+ and (B) CD8+ T cell subsets in
asymptomatic (AS, circles/solid lines, n = 24) and symptomatic (S, squares/dash lines, n = 8) WNV+ subjects 14, 30, 90, and 365 days post-index
donation. The frequencies of the same cells in uninfected controls are displayed (WNV-, triangles, n = 26). The symbols indicate the means and the
error bars represent the SEM. **p ,0.01, *p ,0.05, and *** p ,0.001 by Mann-Whitney. The p-values of the comparison between asymptomatic and
symptomatic groups are indicated by ** adjacent to the cell subset title for p ,0.01 over the time post-index by GEE.
doi:10.1371/journal.pone.0092134.g004
Tim-3+ T Cell Dynamics and WNV Disease Outcome
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Figure 5. Gating strategy for phenotyping IFN-c secreting T cells in response to stimulation. The frequencies of Tim-3+ and Tim-32 IFN-c
secreting CD4+ and CD8+ T cells were measured in PBMC collected at day 30 post-index from 6 HLA-A02 WNV-infected donors and incubated with or
Tim-3+ T Cell Dynamics and WNV Disease Outcome
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